Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36

Benzinga · 1d ago
Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.